Paul Nicklin, PhD joined the Boehringer Ingelheim Venture Fund (BIVF) as an investment manager in 2025, focusing on innovative life science investments in Europe.

Paul is a seasoned leader in pharmaceutical R&D and venture capital, drawing on over 30 years of experience across novel drug discovery and translational research. After earning his Pharmacy degree and PhD in cell biology, Paul began his industry career at Novartis (UK and US), where he led multiple successful pharmacology projects and built cross-functional teams spanning early drug development to clinical research. Paul transitioned to Boehringer Ingelheim, initially heading fibrosis research in the Respiratory Diseases Area, before taking a leading role in external innovation in their Research Beyond Borders department. His strategic mindset and in-depth understanding of the full drug development process have resulted in several clinical development candidates. He has overseen major research collaborations, asset spinouts, and been involved in company leadership.

 Throughout his career, Paul has demonstrated a commitment to advancing projects for areas of high medical need, managing multidisciplinary teams, and fostering cross-industry collaborations that drive innovative therapeutics from concept to clinic. He has a high interest in pursuing drug discovery through external innovation approaches.